Ye Shiying, Sun Shaowei, Cai Jiye, Jiang Jinhuan
Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Curr Mol Pharmacol. 2023;16(7):691-706. doi: 10.2174/1874467216666221130163634.
In recent years, attention has increasingly focused on herbal medicines and their bioactive components attributed to their multi-target pharmacological activity and low side effects. Oridonin is a natural diterpenoid extracted from the traditional Chinese herb and is one of the main active components of Rabdosia rubescens. Modern pharmacological studies have shown that oridonin has anti-tumor, anti-bacterial, anti-inflammatory, anti-oxidant, cardiovascular protective, immunomodulatory, and other effects. Based on the published literature in recent years, we outline the pharmacological activities of oridonin, aiming to provide a theoretical basis for the design and development of new oridonin-based drugs, as well as to facilitate the process of oridonin for clinical use.
近年来,由于草药及其生物活性成分具有多靶点药理活性和低副作用,人们对其关注度日益增加。冬凌草甲素是从传统中药中提取的一种天然二萜类化合物,是冬凌草的主要活性成分之一。现代药理学研究表明,冬凌草甲素具有抗肿瘤、抗菌、抗炎、抗氧化、心血管保护、免疫调节等作用。基于近年来发表的文献,我们概述了冬凌草甲素的药理活性,旨在为新型冬凌草甲素类药物的设计和开发提供理论依据,并促进冬凌草甲素用于临床的进程。